The 5% C-IVIG solution comprised 90% immunoglobulin (IgG, IgM and IgA) with a total anti-SARS-CoV-2 antibody titer three-times higher than in PCP, which makes this treatment potentially more effective than the other passive immunization methods available. The gene discussed is CD79A; the disease is pneumocystosis.